PUMA BIOTECHNOLOGY, INC. (PBYI) Quick Ratio
- Quick ratio · latest quarter: Value 2.57×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 2.57× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $127.96M ÷ $49.83M ≈ 2.57× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 127.96M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 49.83M USD | Liabilities, Current |
| Cash and equivalents | 36.54M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 57.37M USD | Marketable Securities, Current |
| Customer receivables | 34.06M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 13.32M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $127.96M | $49.83M | $36.54M | $57.37M | $34.06M | $13.32M | 2.57× |
| 2026-03-31 | $127.87M | $59.74M | $36.19M | $65.35M | $26.33M | $8.69M | 2.14× |
| 2025-12-31 | $151.18M | $81.25M | $29.64M | $67.89M | $53.65M | $5.51M | 1.86× |
| 2025-09-30 | $127.95M | $82.73M | $53.52M | $40.86M | $33.56M | $9.48M | 1.55× |
| 2025-06-30 | $121.93M | $79.10M | $54.66M | $41.36M | $25.91M | $8.59M | 1.54× |
| 2025-03-31 | $118.34M | $86.66M | $63.03M | $30.14M | $25.17M | $8.75M | 1.37× |
| 2024-12-31 | $132.98M | $96.11M | $69.22M | $31.75M | $32.01M | $8.72M | 1.38× |
| 2024-09-30 | $151.37M | $110.40M | $67.26M | $29.46M | $54.64M | $2.67M | 1.37× |
| 2024-06-30 | $124.94M | $104.30M | $67.15M | $29.68M | $28.11M | $9.05M | 1.20× |
| 2024-03-31 | $131.75M | $98.19M | $76.75M | $30.41M | $24.58M | $7.10M | 1.34× |
| 2023-12-31 | $143.78M | $99.38M | $84.58M | $11.35M | $47.84M | $7.08M | 1.45× |
| 2023-09-30 | $114.00M | $67.36M | $81.80M | $3.23M | $28.97M | $5.68M | 1.69× |
| 2023-06-30 | $105.73M | $60.29M | $60.01M | $14.43M | $31.29M | $7.63M | 1.75× |
| 2023-03-31 | $102.38M | $48.19M | $61.39M | $9.82M | $31.16M | $3.89M | 2.12× |
| 2022-12-31 | $121.42M | $77.48M | $76.20M | $4.87M | $40.35M | $4.53M | 1.57× |
| 2022-09-30 | $105.99M | $59.99M | $77.96M | $0.00 | $28.03M | $5.45M | 1.77× |
| 2022-06-30 | $94.74M | $56.83M | $52.76M | $8.00M | $33.99M | $6.67M | 1.67× |
| 2022-03-31 | $100.95M | $74.79M | $63.91M | $9.99M | $27.04M | $7.28M | 1.35× |
| 2021-12-31 | $114.63M | $109.59M | $63.13M | $18.98M | $32.53M | $7.11M | 1.05× |
| 2021-09-30 | $111.34M | $116.26M | $63.95M | $23.60M | $23.80M | $7.21M | 0.96× |
| 2021-06-30 | $139.52M | $137.90M | $89.85M | $19.13M | $30.55M | $7.62M | 1.01× |
| 2021-03-31 | $135.21M | $140.41M | $95.65M | $13.40M | $26.16M | $7.75M | 0.96× |
| 2020-12-31 | $118.93M | $114.25M | $85.29M | $8.10M | $25.54M | $3.45M | 1.04× |
| 2020-09-30 | $136.16M | $118.20M | $90.08M | $18.94M | $27.14M | $3.14M | 1.15× |
| 2020-06-30 | $131.26M | $94.53M | $90.90M | $16.38M | $23.99M | $2.89M | 1.39× |
| 2020-03-31 | $132.10M | $90.47M | $83.39M | $17.17M | $31.54M | $3.30M | 1.46× |
| 2019-12-31 | $140.54M | $90.84M | $60.04M | $51.61M | $28.90M | $3.17M | 1.55× |
| 2019-09-30 | $137.62M | $88.34M | $58.90M | $51.53M | $27.18M | $3.12M | 1.56× |
| 2019-06-30 | $143.01M | $91.66M | $27.16M | $90.50M | $25.35M | $3.26M | 1.56× |
| 2019-03-31 | $231.39M | $101.40M | $48.79M | $101.62M | $80.98M | $2.64M | 2.28× |
| 2018-12-31 | $186.19M | $67.11M | $108.42M | $57.00M | $20.77M | $2.63M | 2.77× |
| 2018-09-30 | $147.70M | $57.88M | $68.30M | $59.65M | $19.75M | $2.83M | 2.55× |
| 2018-06-30 | $155.85M | $63.53M | $95.91M | $38.60M | $21.34M | $2.48M | 2.45× |
| 2018-03-31 | (m) | $58.12M | $78.55M | (m) | $16.31M | $2.74M | (m) |
| 2017-12-31 | (m) | $58.34M | $81.70M | (m) | $9.67M | $2.03M | (m) |
| 2017-09-30 | $110.23M | $97.25M | $79.72M | $26.62M | $3.89M | $89.00K | 1.13× |
| 2017-06-30 | (m) | $47.24M | $80.82M | $70.83M | (m) | (m) | (m) |
| 2017-03-31 | (m) | $43.73M | $105.09M | $88.89M | (m) | (m) | (m) |
| 2016-12-31 | (m) | $37.46M | $194.49M | $34.98M | (m) | (m) | (m) |
| 2016-09-30 | (m) | $37.60M | $52.54M | $56.39M | (m) | (m) | (m) |
| 2016-06-30 | (m) | $38.97M | $57.84M | $85.95M | (m) | (m) | (m) |
| 2016-03-31 | (m) | $38.91M | $78.22M | $103.00M | (m) | (m) | (m) |
| 2015-12-31 | (m) | $32.44M | $31.57M | $184.32M | (m) | (m) | (m) |
| 2015-09-30 | (m) | $25.33M | $23.60M | $224.18M | (m) | (m) | (m) |
| 2015-06-30 | (m) | $26.10M | $59.84M | $222.53M | (m) | (m) | (m) |
| 2015-03-31 | (m) | $26.08M | $155.47M | $154.86M | (m) | (m) | (m) |
| 2014-12-31 | (m) | $44.44M | $38.54M | $102.79M | (m) | (m) | (m) |
| 2014-09-30 | (m) | $29.36M | $28.26M | $125.60M | (m) | (m) | (m) |
| 2014-06-30 | (m) | $27.93M | $55.36M | $123.00M | (m) | (m) | (m) |
| 2014-03-31 | (m) | $20.24M | $163.38M | $32.73M | (m) | (m) | (m) |
| 2013-12-31 | (m) | $19.27M | $43.04M | $40.90M | (m) | (m) | (m) |
| 2013-09-30 | (m) | $19.23M | $51.26M | $44.38M | (m) | (m) | (m) |
| 2013-06-30 | (m) | $19.82M | $60.90M | $46.62M | (m) | (m) | (m) |
| 2013-03-31 | (m) | $21.63M | $91.65M | $27.07M | (m) | (m) | (m) |
| 2012-12-31 | (m) | $21.70M | $137.41M | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | $26.66M | $33.35M | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | $15.54M | $41.00M | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | $9.48M | $50.17M | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $586.21K | $53.38M | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | $25.47K | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | $1.75K | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | $462.00 | (m) | (m) | (m) | (m) |
| 2010-09-15 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $1.80K | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $2.41K | (m) | (m) | (m) | (m) |
| 2007-04-26 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |